Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4304006 | 1.00 | HSD17B10 (0.42) | HSD17B10ACEPREPSMN1; SMN2EPHX1 | |
| SCHEMBL7257268 | 1.00 | HSD17B10 (0.42) | HSD17B10ACEPREPSMN1; SMN2EPHX1 | |
| SCHEMBL6480541 | 1.00 | HSD17B10 (0.42) | HSD17B10ACEPREPSMN1; SMN2EPHX1 | |
| SCHEMBL6480535 | 1.00 | HSD17B10 (0.42) | HSD17B10ACEPREPSMN1; SMN2EPHX1 | |
| SCHEMBL4304003 | 1.00 | HSD17B10 (0.42) | HSD17B10ACEPREPSMN1; SMN2EPHX1 | |
| SCHEMBL24113253 | 1.00 | HSD17B10 (0.42) | HSD17B10ACEPREPSMN1; SMN2EPHX1 | |
| SCHEMBL15184282 | 0.97 | HSD17B10 (0.42) | HSD17B10ACEPREPSMN1; SMN2NR1H2 | |
| SCHEMBL19205208 | 0.97 | HSD17B10 (0.42) | HSD17B10ACEPREPSMN1; SMN2NR1H2 | |
| SCHEMBL2966911 | 0.97 | HSD17B10 (0.42) | HSD17B10ACEPREPSMN1; SMN2NR1H2 | |
| SCHEMBL6346470 | 0.97 | HSD17B10 (0.42) | HSD17B10ACEPREPSMN1; SMN2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069376-A1 | VLA-4 Antagonists | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| US-20090069376-A1 | VLA-4 Antagonists | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| WO-2006115918-A2 | VLA-4 ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-6800434-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6800434-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069376-A1 | VLA-4 Antagonists | VCAM1, SELPLG, ITGB4 | HSD17B10 4654/4885ACE 3290/4885PREP 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.